Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia

A double-blind controlled study

Ryuzo Ohno, Shuichi Miyawaki, Kiyohiko Hatake, Kazutaka Kuriyama, Kenji Saito, Akihisa Kanamaru, Tohru Kobayashi, Yoshihisa Kodera, Kiyoshi Nishikawa, Shin Matsuda, Osamu Yamada, Eijiro Omoto, Hideo Takeyama, Koji Tsukuda, Norio Asou, Mitsune Tanimoto, Hiroko Shiozaki, Masao Tomonaga, Tohru Masaoka, Yasusada Miura & 3 others Fumimaro Takaku, Yasuo Ohashi, Kazuo Motoyoshi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose: To determine whether macrophage colony-stimulating factor (M- CSF) reduces the incidence and duration of febrile neutropenia during three courses of intensive consolidation therapy and whether it shortens time to complete consolidation therapy. Patients and Methods: In 198 adult patients with acute myeloid leukemia (AML) in complete remission (CR), M-CSF (8 x 106 U/d) or placebo was administered from I day after the end of each consolidation chemotherapy for 14 days. Results: The duration and incidence of febrile neutropenia was significantly reduced by 34% (P = .00285) and 17% (P = .02065), respectively, in 88 assessable patients in the M-CSF group compared with those in 94 assessable patients in the placebo group. Patients in the M-CSF group had 565 days and 133 episodes of febrile neutropenia during 7,901 days at risk, while patients in the placebo group had 977 days and 185 episodes during 9,077 days at risk: The median period required to finish the three courses of consolidation therapy was 93 days in the M-CSF group, which was significantly shorter than 110 days in placebo group (P = .0050). In the M-CSF group, the recovery of neutrophils and platelets was significantly foster (P = .0348 and P = 0.0364, respectively); the administration of systemic antimicrobial agents tended to be less (P = .0839), and the frequency of platelet transfusion (P = .0259) and the total volume of transfused platelets (P = .0292) were significantly less. However, there was no significant difference in the disease-free survival. Conclusion: M-CSF significantly reduced the incidence and duration of febrile neutropenia during the intensive consolidation therapy, and shortened the time to complete consolidation chemotherapy in AML.

Original languageEnglish
Pages (from-to)2954-2965
Number of pages12
JournalJournal of Clinical Oncology
Volume15
Issue number8
Publication statusPublished - Aug 1997
Externally publishedYes

Fingerprint

Febrile Neutropenia
Macrophage Colony-Stimulating Factor
Double-Blind Method
Acute Myeloid Leukemia
Incidence
Consolidation Chemotherapy
Placebos
Therapeutics
Blood Platelets
Platelet Transfusion
Anti-Infective Agents
Disease-Free Survival
Neutrophils

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia : A double-blind controlled study. / Ohno, Ryuzo; Miyawaki, Shuichi; Hatake, Kiyohiko; Kuriyama, Kazutaka; Saito, Kenji; Kanamaru, Akihisa; Kobayashi, Tohru; Kodera, Yoshihisa; Nishikawa, Kiyoshi; Matsuda, Shin; Yamada, Osamu; Omoto, Eijiro; Takeyama, Hideo; Tsukuda, Koji; Asou, Norio; Tanimoto, Mitsune; Shiozaki, Hiroko; Tomonaga, Masao; Masaoka, Tohru; Miura, Yasusada; Takaku, Fumimaro; Ohashi, Yasuo; Motoyoshi, Kazuo.

In: Journal of Clinical Oncology, Vol. 15, No. 8, 08.1997, p. 2954-2965.

Research output: Contribution to journalArticle

Ohno, R, Miyawaki, S, Hatake, K, Kuriyama, K, Saito, K, Kanamaru, A, Kobayashi, T, Kodera, Y, Nishikawa, K, Matsuda, S, Yamada, O, Omoto, E, Takeyama, H, Tsukuda, K, Asou, N, Tanimoto, M, Shiozaki, H, Tomonaga, M, Masaoka, T, Miura, Y, Takaku, F, Ohashi, Y & Motoyoshi, K 1997, 'Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: A double-blind controlled study', Journal of Clinical Oncology, vol. 15, no. 8, pp. 2954-2965.
Ohno, Ryuzo ; Miyawaki, Shuichi ; Hatake, Kiyohiko ; Kuriyama, Kazutaka ; Saito, Kenji ; Kanamaru, Akihisa ; Kobayashi, Tohru ; Kodera, Yoshihisa ; Nishikawa, Kiyoshi ; Matsuda, Shin ; Yamada, Osamu ; Omoto, Eijiro ; Takeyama, Hideo ; Tsukuda, Koji ; Asou, Norio ; Tanimoto, Mitsune ; Shiozaki, Hiroko ; Tomonaga, Masao ; Masaoka, Tohru ; Miura, Yasusada ; Takaku, Fumimaro ; Ohashi, Yasuo ; Motoyoshi, Kazuo. / Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia : A double-blind controlled study. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 8. pp. 2954-2965.
@article{711b25664830400c8744eba8ecb1b478,
title = "Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: A double-blind controlled study",
abstract = "Purpose: To determine whether macrophage colony-stimulating factor (M- CSF) reduces the incidence and duration of febrile neutropenia during three courses of intensive consolidation therapy and whether it shortens time to complete consolidation therapy. Patients and Methods: In 198 adult patients with acute myeloid leukemia (AML) in complete remission (CR), M-CSF (8 x 106 U/d) or placebo was administered from I day after the end of each consolidation chemotherapy for 14 days. Results: The duration and incidence of febrile neutropenia was significantly reduced by 34{\%} (P = .00285) and 17{\%} (P = .02065), respectively, in 88 assessable patients in the M-CSF group compared with those in 94 assessable patients in the placebo group. Patients in the M-CSF group had 565 days and 133 episodes of febrile neutropenia during 7,901 days at risk, while patients in the placebo group had 977 days and 185 episodes during 9,077 days at risk: The median period required to finish the three courses of consolidation therapy was 93 days in the M-CSF group, which was significantly shorter than 110 days in placebo group (P = .0050). In the M-CSF group, the recovery of neutrophils and platelets was significantly foster (P = .0348 and P = 0.0364, respectively); the administration of systemic antimicrobial agents tended to be less (P = .0839), and the frequency of platelet transfusion (P = .0259) and the total volume of transfused platelets (P = .0292) were significantly less. However, there was no significant difference in the disease-free survival. Conclusion: M-CSF significantly reduced the incidence and duration of febrile neutropenia during the intensive consolidation therapy, and shortened the time to complete consolidation chemotherapy in AML.",
author = "Ryuzo Ohno and Shuichi Miyawaki and Kiyohiko Hatake and Kazutaka Kuriyama and Kenji Saito and Akihisa Kanamaru and Tohru Kobayashi and Yoshihisa Kodera and Kiyoshi Nishikawa and Shin Matsuda and Osamu Yamada and Eijiro Omoto and Hideo Takeyama and Koji Tsukuda and Norio Asou and Mitsune Tanimoto and Hiroko Shiozaki and Masao Tomonaga and Tohru Masaoka and Yasusada Miura and Fumimaro Takaku and Yasuo Ohashi and Kazuo Motoyoshi",
year = "1997",
month = "8",
language = "English",
volume = "15",
pages = "2954--2965",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia

T2 - A double-blind controlled study

AU - Ohno, Ryuzo

AU - Miyawaki, Shuichi

AU - Hatake, Kiyohiko

AU - Kuriyama, Kazutaka

AU - Saito, Kenji

AU - Kanamaru, Akihisa

AU - Kobayashi, Tohru

AU - Kodera, Yoshihisa

AU - Nishikawa, Kiyoshi

AU - Matsuda, Shin

AU - Yamada, Osamu

AU - Omoto, Eijiro

AU - Takeyama, Hideo

AU - Tsukuda, Koji

AU - Asou, Norio

AU - Tanimoto, Mitsune

AU - Shiozaki, Hiroko

AU - Tomonaga, Masao

AU - Masaoka, Tohru

AU - Miura, Yasusada

AU - Takaku, Fumimaro

AU - Ohashi, Yasuo

AU - Motoyoshi, Kazuo

PY - 1997/8

Y1 - 1997/8

N2 - Purpose: To determine whether macrophage colony-stimulating factor (M- CSF) reduces the incidence and duration of febrile neutropenia during three courses of intensive consolidation therapy and whether it shortens time to complete consolidation therapy. Patients and Methods: In 198 adult patients with acute myeloid leukemia (AML) in complete remission (CR), M-CSF (8 x 106 U/d) or placebo was administered from I day after the end of each consolidation chemotherapy for 14 days. Results: The duration and incidence of febrile neutropenia was significantly reduced by 34% (P = .00285) and 17% (P = .02065), respectively, in 88 assessable patients in the M-CSF group compared with those in 94 assessable patients in the placebo group. Patients in the M-CSF group had 565 days and 133 episodes of febrile neutropenia during 7,901 days at risk, while patients in the placebo group had 977 days and 185 episodes during 9,077 days at risk: The median period required to finish the three courses of consolidation therapy was 93 days in the M-CSF group, which was significantly shorter than 110 days in placebo group (P = .0050). In the M-CSF group, the recovery of neutrophils and platelets was significantly foster (P = .0348 and P = 0.0364, respectively); the administration of systemic antimicrobial agents tended to be less (P = .0839), and the frequency of platelet transfusion (P = .0259) and the total volume of transfused platelets (P = .0292) were significantly less. However, there was no significant difference in the disease-free survival. Conclusion: M-CSF significantly reduced the incidence and duration of febrile neutropenia during the intensive consolidation therapy, and shortened the time to complete consolidation chemotherapy in AML.

AB - Purpose: To determine whether macrophage colony-stimulating factor (M- CSF) reduces the incidence and duration of febrile neutropenia during three courses of intensive consolidation therapy and whether it shortens time to complete consolidation therapy. Patients and Methods: In 198 adult patients with acute myeloid leukemia (AML) in complete remission (CR), M-CSF (8 x 106 U/d) or placebo was administered from I day after the end of each consolidation chemotherapy for 14 days. Results: The duration and incidence of febrile neutropenia was significantly reduced by 34% (P = .00285) and 17% (P = .02065), respectively, in 88 assessable patients in the M-CSF group compared with those in 94 assessable patients in the placebo group. Patients in the M-CSF group had 565 days and 133 episodes of febrile neutropenia during 7,901 days at risk, while patients in the placebo group had 977 days and 185 episodes during 9,077 days at risk: The median period required to finish the three courses of consolidation therapy was 93 days in the M-CSF group, which was significantly shorter than 110 days in placebo group (P = .0050). In the M-CSF group, the recovery of neutrophils and platelets was significantly foster (P = .0348 and P = 0.0364, respectively); the administration of systemic antimicrobial agents tended to be less (P = .0839), and the frequency of platelet transfusion (P = .0259) and the total volume of transfused platelets (P = .0292) were significantly less. However, there was no significant difference in the disease-free survival. Conclusion: M-CSF significantly reduced the incidence and duration of febrile neutropenia during the intensive consolidation therapy, and shortened the time to complete consolidation chemotherapy in AML.

UR - http://www.scopus.com/inward/record.url?scp=0030762655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030762655&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 2954

EP - 2965

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -